A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens
Sven Kratochvil, Paul F McKay, Jakub T Kopycinski, Cynthia Bishop, Peter John Hayes, Luke Muir, Christopher L Pinder, Deniz Cizmeci, Deborah King, Yoann Aldon, Bruce D Wines, P Mark Hogarth, Amy W Chung, Stephen J Kent, Kathrin Held, Christof Geldmacher, Len Dally, Nelson S Santos, Tom Cole, Jill Gilmour Show all
FRONTIERS IN IMMUNOLOGY | FRONTIERS MEDIA SA | Published : 2017
A key aspect to finding an efficacious human immunodeficiency virus (HIV) vaccine is the optimization of vaccine schedules that can mediate the efficient maturation of protective immune responses. In the present study, we investigated the effect of alternate booster regimens on the immune responses to a candidate HIV-1 clade C CN54gp140 envelope protein, which was coadministered with the TLR4-agonist glucopyranosyl lipid A-aqueous formulation. Twelve study participants received a common three-dose intramuscular priming series followed by a final booster at either 6 or 12 months. The two homologous prime-boost regimens were well tolerated and induced CN54gp140-specific responses that were obs..View full abstract
Awarded by Wellcome Trust via UKHVC
Awarded by European Union's Horizon 2020 research and innovation program
Awarded by Australian NHMRC-EU
This study was funded by the International AIDS Vaccine Initiative (IAVI), and conduct of the clinical study was supported by the NIHR at Imperial College Healthcare NHS Trust. Provision of CN54gp140 and GLA-AF was supported through core funding from the Wellcome Trust via UKHVC (083844/Z/07/Z). The Fc-functional antibody work was funded by the European Union's Horizon 2020 research and innovation program under grant agreement no. 681032 and an Australian NHMRC-EU collaborative grant #1115828.